Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
(2015). The therapeutic monoclonal antibody market. mAbs: Vol. 7, No. 1, pp. 9-14. doi: 10.4161/19420862.2015.989042 Via Krishan Maggon 
|
Scoop.it!
Gilbert C FAURE's insight:
impressive for immunologists so far away from so big amounts of money
Krishan Maggon 's curator insight,
January 6, 2014 8:38 AM
Abstract
A review of the best selling monoclonal antibodies in 2013 and 2012 is provided. Humira with sales of over $11 billion ($9.3 billion in 2012) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2013 as in 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012 Table. Remicade (9.7 Bn), Rituxan (7.5 Bn) , Herceptin (6.5 Bn) and Avastin (6.5 Bn) were the second, third, fourth and fifth top selling mabs in 2013. The actual sales for 2013 as reported by the companies are provided. The total sales of the top selling blockbuster mabs were $63 billion in 2013. The actual global sales of all the approved blockbuster sales or potential (sales >1 billion) monoclonal antibodies in 2013 is provided. Besides the top 5 mabs, there were 2 other monoclonal antibodies with sales of over 2 billion dollars and 5 with sales of over $ 1 billion in 2013. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 30 monoclonal antibodies are marketed in the US and Europe (January 2014). Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs.
|
pages 9-14
Publishing models and article dates explainedReceived: 16 Sep 2014Accepted: 12 Nov 2014Accepted author version posted online: 20 Dec 2014Published online: 14 Jan 2015